Momentum Biotechnologies

What Momentum Biotechnologies does

Momentum Biotechnologies (legal entity PureHoney Technologies, Inc.) is a United States-based contract research organization that provides mass spectrometry-based drug discovery and proteomics services to pharmaceutical and biotechnology clients. Founded in 2014 as PureHoney Technologies, the company rebranded to Momentum Biotechnologies in February 2023 and is headquartered in a 20,000 SF purpose-built facility in Billerica, Massachusetts, which houses capacity for up to 40 mass spectrometers, BSL-2 labs, and integrated sample preparation. The company's core technology stack is anchored by RapidFire-MS (originally commercialized by the founding team) and Orbitrap-class instruments, supplemented by 17+ proprietary Scout™ assay platforms covering target identification, covalent and non-covalent binding, chemoproteomics, ubiquitinome and turnover profiling, and label-free target deconvolution (most recently CHIPP, launched May 2026). Complementary data products—the Protein Turnover Atlas (16,000+ proteins across ~50 cell lines) and Mouse Turnover Atlas (22 tissues/biofluids)—provide on-demand access to curated baseline turnover data.

The company operates a fee-for-service CRO model with project-specific, quote-based pricing negotiated directly with enterprise pharma and biotech clients; PhD-trained scientists engage from first contact. Distribution is sales-led and direct, supplemented by strategic partnerships (Axxam for chemical library access; Cube Biotech for membrane protein screening) that extend service reach without internal capital deployment. In March 2025, Momentum acquired Munich-based OmicScouts GmbH, establishing European operations under the Momentum Europe brand and adding OmicScouts' co-founders (Dr. Bernhard Küster and Dr. Mathias Wilhelm of TUM) to its Scientific Advisory Board. The European entity is headquartered in Freising, Germany. Customer segments are defined horizontally (pharmaceutical and biotechnology companies) and by use case (next-generation modality developers working on PROTACs, molecular glues, and covalent drugs), with therapeutic area coverage spanning oncology, immunology, neuroscience, metabolic disease, infectious disease, and rare diseases. The company employs 11–50 people and is privately held with no disclosed institutional investors.

Name

Momentum Biotechnologies

Legal name

PureHoney Technologies, Inc.

Website

https://momentum.bio

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Momentum Biotechnologies is a US-based contract research organization specializing in mass spectrometry-based drug discovery and proteomics services, serving pharmaceutical and biotechnology clients with proprietary Scout™ assay platforms and 40 mass spectrometer capacity from Billerica, MA and Freising, Germany.

Ownership category

akta.pro rank

Product category

Contract Research Services (Drug Discovery CRO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Mass spectrometry services
• Contract research organization
• Proteomics profiling services
• Drug discovery CRO
• Chemoproteomics screening

Headquarters

HQ city

Billerica

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service CRO model providing mass spectrometry-based drug discovery services including screening, proteomics, and chemoproteomics. Services support all stages of preclinical research from target identification through preclinical development. Projects are initiated via client inquiry and direct scientific engagement.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Momentum Biotechnologies is a contract research organization (CRO) that delivers mass spectrometry-based drug discovery and proteomics services to pharmaceutical and biotechnology clients. The company provides high-throughput screening, chemoproteomic profiling, covalent and non-covalent binding characterization, biomarker analysis, and proprietary data products that support target identification, lead generation, and preclinical development. Services are powered by the company's RapidFire-MS, Orbitrap, and ICP-MS instrumentation, supported by an integrated suite of proprietary Scout™ chemoproteomic platforms and a 20,000 SF BSL-2-capable research facility.

Product overview

Momentum Biotechnologies is a contract research organization (CRO) specializing in mass spectrometry-based drug discovery services. The company operates a platform of integrated technologies organized around core screening and proteomics services, including Affinity Selection Mass Spectrometry (ASMS), Covalent Binding Assays, Proteomics & Chemoproteomics, Small Molecule Analysis, Oligo Analysis, and Data Products. These services are powered by a suite of proprietary technology platforms (Scout™ platforms including UbiScout™, TurnoverScout™, TargetScout™, CysScout™, ProteomeScout™, SignalingScout™, SurfaceScout™, DecryptM, KinomeScout™, QuantScout™, PhotoTargetScout™, NucleoBeads™, PlasmaScout™, SPICE, and CHIPP) and supported by advanced instrumentation platforms (RapidFire-MS, ICP-MS, Orbitrap Astral Zoom, Orbitrap Ascend). The company operates under both Momentum Biotechnologies and Momentum Europe brands, with the recent acquisition of OmicScouts expanding their European presence and proteomic capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Affinity Selection Mass Spectrometry (ASMS) High-throughput screening service using solution-based, label-free mass spectrometry to identify small molecule binders against proteins, multi-protein complexes, and RNA/DNA oligos for pharmaceutical and biotech drug discovery clients.
• Covalent Binding Assays Service using Intact MS and peptide mapping to identify, validate, and prioritize irreversible covalent binders for pharmaceutical and biotech covalent drug discovery programs.
• Proteomics & Chemoproteomics

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature19 records

Partnerships

Three partnerships are on record, tiered core.

• OmicScouts GmbHcoreStrategic or Co-development Partner · 5 March 2025Acquisition completed March 5, 2025 expands Momentum's geographic reach into Europe and enhances its proteomic service portfolio. OmicScouts, based in Munich, Germany, is a CRO and proteomics leader specializing in mass spectrometry-based proteomics. The co-founders (Dr. Bernhard Küster and Dr. Mathias Wilhelm from TUM) joined Momentum's Scientific Advisory Board. Now operating as 'OmicScouts, A Momentum Biotechnologies Company'.
• Cube BiotechcoreTechnology or Integration · 8 August 2024Strategic partnership announced August 8, 2024 enables Momentum to leverage Cube Biotech's NativeMP technology for solubilization and stabilization of membrane proteins without compromising native conformation. This allows challenging membrane protein targets (such as GLP1 receptor) to be effectively screened via ASMS. The partnership addresses a key challenge in drug discovery where membrane proteins are difficult to express and stabilize for screening.
• Axxam S.p.A.coreStrategic or Co-development Partner · 16 November 2023Partnership announced November 16, 2023 enables Axxam's highly curated chemical diversity library (325,000 compounds) to be available for high-throughput screening using Momentum's mass spectrometry-based functional and binding assay platforms. Primary hits can be progressed in hit-to-lead projects with downstream experiments including cell-based assays. The collaboration expands both companies' service offerings and provides clients access to additional chemical matter for drug discovery programs.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Biognosys AG: Swiss proteomics CRO specializing in mass spectrometry-based protein quantification and discovery services, explicitly named alongside Momentum as a major player in the CRO mass spectroscopy services market.
• Creative Proteomics: Specialized proteomics CRO providing mass spectrometry-based protein identification, quantification, and characterization services to pharma and biotech clients.

Broad incumbents

• Thermo Fisher Scientific: Manufacturer of Orbitrap MS platforms that Momentum uses, and increasingly offers adjacent proteomics services and software through its life sciences services division.
• Eurofins Scientific: Large global CRO offering broad bioanalytical and proteomics services including mass spectrometry-based biomarker and discovery work across pharma and biotech.
• Charles River Laboratories: Major preclinical CRO providing discovery and safety assessment services, including MS-based bioanalytical offerings to pharma and biotech clients.
• Evotec SE: Global drug discovery CRO offering end-to-end services including proteomics and MS-based screening capabilities for pharma and biotech partners.
• WuXi AppTec: Large global CRO with extensive proteomics and bioanalytical service offerings across the drug discovery and development value chain.
• Cell Signaling Technology: Established life science tools and proteomics services company providing antibody-based and MS-based protein analysis for research and drug discovery customers.
• Promega Corporation: Life science tools provider with growing proteomics and mass spectrometry reagent and service offerings relevant to drug discovery research.

Emerging players

• Reaction Biology Corporation: CRO offering specialized biochemical and biophysical assay services including mass spectrometry-based target engagement and selectivity profiling for drug discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/momentumbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Momentum Biotechnologies